ANI Pharmaceuticals (NASDAQ:ANIP) CFO Stephen Carey Sells 2,850 Shares

Key Points

• CFO Stephen Carey sold 2,850 ANI Pharmaceuticals shares at an average price of $72.80, totaling $207,480, under a pre-arranged Rule 10b5-1 trading plan. He retained 171,843 shares after the sale.
• ANI Pharmaceuticals shares fell 1.8% to $71.92, near the company’s 12-month low of $70.15. The stock has a market capitalization of approximately $1.65 billion.
• The company recently exceeded quarterly earnings and revenue expectations, reporting $2.21 EPS and $266.04 million in revenue, while analysts maintain a “Moderate Buy” consensus with an average price target of $105.83.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen Carey sold 2,850 shares of the stock in a transaction on Monday, August 31st. The shares were sold at an average price of $72.80, for a total value of $207,480.00. Following the completion of the sale, the chief financial officer owned 171,843 shares of the company's stock, valued at $12,510,170.40. The trade was a 1.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ANI Pharmaceuticals Stock Down 1.8%

Shares of ANIP stock traded down $1.33 on Tuesday, reaching $71.92. 580,537 shares of the company's stock traded hands, compared to its average volume of 381,070. ANI Pharmaceuticals, Inc. has a 12-month low of $70.15 and a 12-month high of $99.50. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The company has a market capitalization of $1.65 billion, a P/E ratio of 15.50 and a beta of 0.44. The business's 50 day moving average price is $79.53 and its two-hundred day moving average price is $78.59.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million during the quarter, compared to the consensus estimate of $260.13 million. During the same period in the prior year, the business earned $1.80 EPS. The business's revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

Analysts Set New Price Targets

ANIP has been the subject of several research reports. Guggenheim decreased their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a report on Monday, August 10th. Weiss Ratings lowered shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Canaccord Genuity Group cut their target price on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 14th. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $105.83.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Penn Capital Management Company LLC grew its position in ANI Pharmaceuticals by 2,058.9% in the fourth quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company's stock worth $10,858,000 after acquiring an additional 131,030 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company's stock valued at $103,022,000 after purchasing an additional 27,598 shares during the last quarter. CenterBook Partners LP acquired a new stake in shares of ANI Pharmaceuticals in the 4th quarter valued at $1,518,000. NFJ Investment Group LLC bought a new stake in ANI Pharmaceuticals in the second quarter worth $2,766,000. Finally, Walleye Capital LLC bought a new stake in ANI Pharmaceuticals in the second quarter worth $8,784,000. Institutional investors and hedge funds own 76.05% of the company's stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source